Advertisement

Related Videos

Peter Clark, MA, MD, FRCP: A Payer Perspective

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

David A. Hyman, MD, JD, on Inclusive Shared Savings

Advertisement

Advertisement




Oct
08
Today In Oncology
FDA Approves First-Line Pirtobrutinib for CLL-SLL
FDA Approves Lirafugratinib for Previously Treated, Unresectable, Locally Advanced or Metastatic Cholangiocarcinoma
FDA Approves New Labeling of ROS1 Inhibitor for NSCLC
Charles Perou 2026 William L. McGuire Memorial Lecture Award
Starting Surveillance Colonoscopy After High-Risk Adenoma Removal When Is the Right Time
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo